849606-97-9

Upstream product

• 849606-95-7 2-amino-N¹-[2-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-ethyl]-succinamide 
• 849606-94-6 {2-carbamoyl-1-[2-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 190324-44-8 N¹-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)ethane-1,2-diamine 
• 849606-96-8 (1-{2-carbamoyl-1-[2-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-ethylcarbamoyl]-ethylcarbamoyl}-cyclohexyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 

Downstream Products

• 849606-98-0 N-(1-{2-carbamoyl-1-[2-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-ethylcarbamoyl]-ethylcarbamoyl}-cyclohexyl)-3-[4-(di-tert-butoxy-phosphorylmethyl)-benzyl]-succinamic acid tert-butyl ester 

Relevant academic research and scientific papers

Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic

Fluorescence labeling has become a general technique for studying the intracellular accumulation and localization of exogenously administered materials. Reported herein is a low nanomolar affinity Grb2 SH2 domain-binding antagonist that utilizes the environmentally-sensitive nitrobenzoxadiazole (NBD) fluorophore as a naphthyl replacement. This novel agent should serve as a useful tool to visualize the actions of this class of Grb2 SH2 domain-binding antagonists in whole cell systems.